Mana.bio
AI-powered platform for developing lipid nanoparticles for oligonucleotide therapies.
About
Technology stack
detected 2026-06-18No comments yet. Be the first to share your take.
What does Mana.bio do?
Mana.bio is an AI-based drug delivery startup focused on gene therapy, including DNA and RNA-based therapeutics and vaccines. Their technology integrates machine learning and nanotechnology to identify lipid nanoparticle drug delivery systems. They offer ChatLNP, an AI agent named Mina, to help scientists explore literature, predict LNP properties, and optimize formulations.
How much funding has Mana.bio raised?
Mana.bio has raised a total of $20M in funding. The most recent round on record is Seed.
Where is Mana.bio headquartered?
Mana.bio is headquartered in Boston, United States.
When was Mana.bio founded?
Mana.bio was founded in 2021.
What industry does Mana.bio operate in?
Mana.bio operates in Life Sciences, Drug Delivery, mRNA, Lipid Nanoparticle (LNP), Therapeutics, Biotech.
How many employees does Mana.bio have?
Mana.bio has approximately 20 people on record.